Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

COMPOUND FOCUS INC

UEI: SSMJRGH6KD33

COMPOUND FOCUS INC is a federal contractor, registered under UEI SSMJRGH6KD33. It has been awarded $31,611,866 across 53 federal contracts. Primary work spans Research and Development in Biotechnology, Medicinal and Botanical Manufacturing, and Research and Development in the Physical, Engineering, and Life Sciences. Top awarding agencies include Department Of Health And Human Services and Environmental Protection Agency.

Contact Information

Registration and classification details

Registration

UEI Code

SSMJRGH6KD33

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$28.4M89.8%

Environmental Protection Agency$3.2M10.2%

Awards by NAICS

541711 - Research and Development in Biotechnology$22.9M72.6%

325411 - Medicinal and Botanical Manufacturing$5.6M17.7%

541710 - Research and Development in the Physical, Engineering, and Life Sciences$3.1M9.7%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in COMPOUND FOCUS INC's top NAICS codes and agencies

NIRMATRELVIR AND RI

Solicitation # SPE2DP-26-T-4498

The contract specifies the procurement of 50 boxes of PAXLOVID, each containing 10 blister cards with three tablets each—two 150 mg nirmatrelvir tablets and one 100 mg ritonavir tablet—providing a five-day course of treatment with two daily doses per box. The product is manufactured by Pfizer Inc under part number NDC00069-5321-30 and is regulated by the FDA, requiring confirmation via EBS referral. Each box constitutes a complete unit of issue, and the medication must be shipped within 20 days to the delivery point in Williamsburg, Virginia, with no variance allowed in quantity. The shelf life is fixed at 36 months and non-extendable, with packaging required to meet MIL-STD-2073-1E standards and medical marking Standard No. 1, superseding MIL-STD-129. All shipments must be traceable, cannot use parcel post, and must comply with DLA packaging and marking requirements. The contract is issued under solicitation SPE2DP-26-T-4498 with a response deadline of August 11, 2026, and an original required delivery date of April 28, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 5 hours ago

DEADLINE

CALCIUM CHLORIDE INJEC

Solicitation # SPE2DP-26-T-4471

CALCIUM CHLORIDE INJECTION USP is procured as a 10 mL single-dose plastic syringe containing 1 gram of calcium chloride (100 mg/mL), packaged ten syringes per unit (1 PG = 10 EA), with a mandatory 24-month shelf life from the date of manufacture, no less than 21 months of which must remain at the time of delivery to the government. The product must be labeled in strict accordance with Medical Marking Standard No. 1, including the NSN, manufacturer, CAGE code, date of manufacture, expiration or retest date, contract number, and lot number, and stored at 20 to 25°C (68 to 77°F). The item is regulated by the FDA and requires prior confirmation from the product specialist via EBS referral before award. Packaging must be commercial and designed to protect against damage, with exterior shipping containers ensuring safe, cost-effective transport to the delivery point. All packaging and marking must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and palletization must follow DLA Packaging Requirements for Procurement. The manufacturer is Pfizer Inc, with NDC 00409-1631-10, and the item is identified by NSN 6505-01-655-0700. Delivery is FOB destination in 20 days to Fort Campbell, Kentucky, with zero quantity variance permitted, and shipment must occur via traceable means, excluding parcel post. The contract reference is SPE2DP-26-T-4471, with an original required delivery date of August 5, 2026, and procurement governed by the DLA Master List of Technical and Quality Requirements, which take precedence over all other standards including ASTM D3951.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ANALGESIC GEL, TOPICAL

Solicitation # SPE2DP-26-T-4491

The contract solicits a topical analgesic gel containing 5% menthol USP, packaged in 4 oz tubes with 144 tubes per case, designated by NSN 6505-01-658-7643. The product is classified as flammable and must be stored at 20–25°C (68–77°F). It carries a non-extendable shelf life of 24 months and is subject to specific packaging standards under Medical Marking Standard No. 1, superseding MIL-STD-129. Each unit must be sealed in protective containers and packed in commercial shipping containers suitable for safe transport at the lowest carrier rate, with all markings compliant with medical logistics requirements. Hazard communication regulations under OSHA’s revised HCS and 29 C.F.R. 1910.1200 apply, requiring suppliers to submit approved Safety Data Sheets and compliant labels to the contracting officer before award. A current SDS must accompany each shipment and be submitted electronically to DLA.MSDS@DLA.MIL with the required cover sheet. The product must comply with 49 CFR and ICAO regulations for hazardous materials, and suppliers must train employees on these requirements. The solicitation, issued under SPE2DP-26-T-4491, has a response deadline of August 10, 2026, with delivery to Fort Campbell, Tennessee, required within 20 days of award.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

SUMATRIPTAN SUCCINATE

Solicitation # SPE2DP-26-T-4473

Sumatriptan Succinate Tablets, 100mg, are supplied in bottles of nine tablets and are indicated for the acute treatment of migraine with or without aura in adults. The product must be stored at 20 to 25°C (68 to 77°F) and protected from light, complying with USP controlled room temperature standards. It is subject to a non-extendable 24-month shelf life under Type I (Code M) requirements, with packaging and marking mandated to adhere to MIL-STD-2073-1E and MIL-STD-129, as well as the latest Medical Marking Standard No. 1. The supply is regulated by the FDA, and contractors must provide detailed manufacturer and product information for official verification. Two line items total two bottles, with delivery required within five days to two separate military addresses: one at Joint Base Elmendorf-Richardson, Alaska, and the other at Ramstein Air Base, Germany. Both shipments are FOB destination, with zero variance allowed in quantity, and inspection and acceptance occur at the delivery point. The contract includes DLA-specific packaging, procurement, and logistics requirements, referencing technical standards from the DLA Master List, and is issued under solicitation SPE2DP-26-T-4473 with a required delivery date of August 5–6, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DDDPlus Software Licensing and SupportThe contract entails the provision of five individual Standard licenses for DDDPlus software, covering full delivery, installation, and compatibility testing to ensure seamless integration with existing systems. License administration will be maintained throughout a four-year term, including ongoing support and compliance management. The work is performance-based with the place of performance located in Silver Spring, Maryland, under a subcontract structure, and falls under the NAICS code 511210 for software publishing. The Department of Health and Human Services is the contracting organization, with a response deadline set for August 14, 2026, and the solicitation was posted on August 4, 2026. All activities must align with federal procurement standards and deliverables must meet technical and operational requirements specified in the agreement.

Department Of Health And Human Services

POSTED

DEADLINE

GastroPlus Software Licensing and SupportThe contract awards the supply and ongoing support of 20 Standard licenses for GastroPlus software over a four-year period, encompassing full delivery, installation, and verification of compatibility with FDA systems. The provider is responsible for ensuring seamless integration into existing infrastructure and managing all aspects of license administration throughout the term. Performance is required to occur at the designated location in Silver Spring, Maryland, with the work falling under NAICS code 511210 for software publishing. The opportunity was posted on August 4, 2026, and responses are due by August 14, 2026, with the contracting entity being the Department of Health and Human Services. This subcontract supports critical regulatory and scientific operations that rely on GastroPlus for pharmacokinetic and pharmacodynamic modeling within federal health and safety contexts.

Department Of Health And Human Services

POSTED

DEADLINE

Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription

Solicitation # 7571TE26Q00153

The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.

Department Of Health And Human Services

POSTED

DEADLINE

MAGNESIUM SULFATE

Solicitation # SPE2DP-26-T-4456

MAGNESIUM SULFATE 495MG/5GM oral granules in 454GM bags, sold in cases of 12 bags each, is procured under contract SPE2DP-26-T-4456 for delivery to the USS THEODORE ROOSEVELT CVN 71 at FPO AP 96632 with a five-day delivery window and no tolerance for quantity variance. The product is classified as a TYPE I (CODE Q) medical item with a non-extendable shelf life of 36 months and must comply with Medical Marking Standard No. 1, which supersedes all references to MIL-STD-129. All packaging must meet commercial standards as specified in DLA’s procurement requirements, ensuring each unit is sealed in protective containers and packed in exterior shipping containers suitable for safe, low-cost transport by common carrier to the destination. Palletization and labeling must adhere to DLA’s Packaging Requirements for Procurement and the latest version of Medical Marking Standard No. 1, available through DLA Troop Support or their official website. The item is identified by NSN 6505-01-714-4975 and NDC 46122-0461-43, supplied by AMERISOURCEBERGEN DRUG CORP, and shipped via traceable methods only—parcel post is prohibited. Delivery is FOB destination with inspection and acceptance also occurring at the point of delivery, and the required delivery date is August 5, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

Unable to Decompose Subcontract OpportunitiesDue to a system error, the prime contract details necessary to identify or structure subcontract opportunities could not be retrieved, rendering all subcontracting analysis unavailable at this time. The solicitation is designated as a subcontract under the Department of Health and Human Services, with a posted date of August 3, 2026, and a response deadline of August 18, 2026. The place of performance is listed as Bethesda, Maryland, with a zip code of 20892, though no specific office address, point of contact, or set-aside information is provided. The NAICS code is marked as NA, and the agency and organizational designations are identical, indicating an internal system limitation. Despite the absence of actionable data for suppliers, the opportunity remains live in the system with a public view link available for reference.

Department Of Health And Human Services

POSTED

DEADLINE

Antioxidant Therapy for Smith-Lemli-Opitz Syndrone

Solicitation # NICHD-08610

The contract pertains to the development and implementation of antioxidant therapy for Smith-Lemli-Opitz Syndrome, a rare genetic disorder characterized by multiple congenital anomalies and metabolic dysfunction. The solicitation, issued under NICHD-08610 by the Department of Health and Human Services through its National Institutes of Health, invites proposals aimed at advancing targeted antioxidant interventions to mitigate the pathological effects of the condition. The opportunity was posted on August 3, 2026, with responses due by August 18, 2026, at 2:00 PM Eastern Time. The work is expected to be performed in Bethesda, Maryland, consistent with the research infrastructure of the NIH campus. All proposals must be submitted through the SAM.gov portal and should address scientific rigor, feasibility, and potential clinical impact. The primary point of contact for inquiries is Niamh Cawley, with Chung Huang as the secondary contact, both reachable via NIH email addresses. The contracting activity falls under the Department of Health and Human Services with no set-aside provisions specified, and no NAICS code is assigned, indicating flexibility in contractor categorization. Interested parties should ensure adherence to deadlines and submission requirements outlined on the official UI link linked in the posting.

Department Of Health And Human Services

POSTED

DEADLINE

Manufacturing of CARD Casualty Response Documentation ToolThe contract is for the full production of a durable, field-ready medical documentation card designed to support casualty response operations, adhering strictly to the DLA Master List technical and quality standards. The product must be robust enough for frontline use under demanding conditions and capable of reliably conveying critical medical information in austere environments. Production will be executed as a subcontract under the Department of Defense’s Medical Supply Chain MD Surg FSF, with the place of performance located in WaterVliet, New York, at the ZIP code 12189-5000. The NAICS code 325411 indicates the work falls under pharmaceutical and medicine manufacturing, underscoring the precision and regulatory compliance required in materials and processes. The solicitation was posted on August 2, 2026, with a response deadline of August 10, 2026, allowing potential subcontractors a limited window to submit proposals. The contract type is explicitly labeled as a subcontract, meaning the winning party will be engaged by a prime contractor rather than directly by the government. There is no set-aside classification specified, indicating the opportunity is open to all eligible entities regardless of business size or status. While no point of contact is listed, interested parties can access additional details through the provided DIBBS link, which hosts the official request for quotation. The focus is squarely on delivering a standardized, high-integrity medical documentation tool that meets rigorous military specifications for reliability and performance.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

Supply of Hydrocortisone Cream 2.5% (NSN 6505017157536)The contract entails the procurement and delivery of ten units of Hydrocortisone Cream 2.5% in one-ounce tubes, specifically designated by NSN 6505017157536, ensuring full compliance with FDA regulations and adherence to Department of Defense medical and logistical standards as defined by DLA. All products must meet stringent military medical requirements for quality, packaging, labeling, and shelf life to support operational readiness and field distribution. The solicitation is issued under a subcontract mechanism with a NAICS code of 325411, indicating pharmaceutical manufacturing, and is managed by the Medical Supply Chain Pharm FSA under the Department of Defense. Responses are due by August 10, 2026, with the opportunity posted on August 2, 2026, providing suppliers eight days to submit proposals. The place of performance and point of contact details are not specified, but delivery must fulfill the logistical needs of the Defense Logistics Agency. The contract is accessible through the DIBBS platform, and while no set-aside designation is listed, all offerings must be FDA-approved and aligned with the prescribed military medical specifications for use in deployed and garrison medical facilities.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supplier of Omeprazole Extended-Release Capsules (NSN 6505016247068)The contract solicits suppliers to provide FDA-approved Omeprazole Extended-Release Capsules in bulk quantities that fully comply with National Stock Number NSN 6505016247068 specifications, ensuring eligibility for procurement by the Defense Logistics Agency. The product must meet all regulatory and quality standards required for use within U.S. military medical supply chains and is intended for distribution through the Department of Defense’s Medical Supply Chain Pharmaceutical FSA. Submission deadlines are firm, with responses due by August 10, 2026, and the solicitation is structured as a subcontract under the NAICS code 325411, which pertains to pharmaceutical and biological product manufacturing. All deliveries are to be addressed to the designated place of performance in APO, ZIP 96264-2022, with no additional office address details provided. The contract is posted on the DIBBS platform and is open to qualified manufacturers capable of meeting stringent military pharmaceutical requirements.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE